Clinical trial

An Open-Label Study of E7974 Administered on Days 1, 8, and 15 of a 28-Day Cycle…

NCT00121732 · Eisai Inc., Industry · Completed

Key facts

NCT number NCT00121732
Title An Open-Label Study of E7974 Administered on Days 1, 8, and 15 of a 28-Day Cycle and Days 1 and 8 of a 21-Day Cycle in Patients With Solid Malignancies
Official title A Phase 1, Two-Arm, Open-Label Study of E7974 Administered on Days 1, 8, and 15 of a 28-Day Cycle and Days 1 and 8 of a 21-Day Cycle in Patients With Solid Malignancies
Lead sponsor Eisai Inc., Industry
Status Completed
Phase Phase 1
Study type Interventional
Conditions Solid Tumor Malignancies, Cancer
Intervention type Drug
Interventions E7974
Enrollment 39
Start date Jul 1, 2005
Primary completion Oct 1, 2009
Completion Oct 1, 2009
First posted Jul 21, 2005
Last update posted Jul 1, 2015
Countries United States

At a glance

  • 1–9 Study sites
  • No Results posted
  • None Linked FDA submissions

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About ClinicalTrials.gov studies

ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.

Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date:

Browse all ClinicalTrials.gov studies